Clinical Trials Logo

RRMM clinical trials

View clinical trials related to RRMM.

Filter by:
  • None
  • Page 1

NCT ID: NCT04412707 Terminated - RRMM Clinical Trials

A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients

PORT
Start date: August 4, 2020
Phase: Phase 2
Study type: Interventional

This is a randomized, two-period, cross-over Phase 2 study, comparing PK, and assessing safety and tolerability and efficacy of peripheral and central intravenous administration of melflufen in patients with RRMM. It is an international study, enrolling patients in US and Europe. The study will enroll patients following at least 2 lines of prior therapy.

NCT ID: NCT03778346 Recruiting - RRMM Clinical Trials

Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells

Start date: November 15, 2018
Phase: Phase 1
Study type: Interventional

According to the high expression of tumor cell-associated antigen CD138, integrin β7, CS1, CD38 and BCMA in patients with refractory/recurrent multiple myeloma, the fourth generation of CAR-T cells(simultaneously expressing IL7 and CCL19) with 10 different dual target combinations are used to minimize the tumor burden in the patient individually and precisely and improve the immunosuppressive microenvironment of the tumor , thereby effectively treating refractory/recurrent multiple myeloma .

NCT ID: NCT02684617 Terminated - rrMM Clinical Trials

Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)

Start date: March 29, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) used in combination with dinaciclib (MK-7965) in the treatment of relapsed or refractory chronic lymphocytic leukemia (rrCLL), multiple myeloma (rrMM), or diffuse large B-cell lymphoma (rrDLBCL).